Last updated on October 2018

Study of Adjuvant ONO-4538 With Resected Gastric Cancer


Brief description of study

The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.

Clinical Study Identifier: NCT03006705

Contact Investigators or Research Sites near you

Start Over

Saitama Clinical Site

Kitaadachi-gun, Japan
  Connect »

Busan Clinical Site1

Busan, Korea, Republic of
  Connect »

Busan Clinical Site2

Busan, Korea, Republic of
  Connect »

Daegu Clinical Site1

Daegu, Korea, Republic of
  Connect »

Daegu Clinical Site2

Daegu, Korea, Republic of
  Connect »

Daegu Clinical Site3

Daegu, Korea, Republic of
  Connect »

Gwangju Clinical Site

Gwangju, Korea, Republic of
  Connect »

Gyeonggi-do Clinical Site1

Gyeonggi-do, Korea, Republic of
  Connect »

Gyeonggi-do Clinical Site2

Gyeonggi-do, Korea, Republic of
  Connect »

Gyeonggi-do Clinical Site3

Gyeonggi-do, Korea, Republic of
  Connect »

Gyeonggi-do Clinical Site4

Gyeonggi-do, Korea, Republic of
  Connect »

Jeollabuk-do Clinical Site

Jeollabuk-do, Korea, Republic of
  Connect »

Seoul Clinical Site1

Seoul, Korea, Republic of
  Connect »

Seoul Clinical Site2

Seoul, Korea, Republic of
  Connect »

Seoul Clinical Site3

Seoul, Korea, Republic of
  Connect »

Seoul Clinical Site4

Seoul, Korea, Republic of
  Connect »

Seoul Clinical Site5

Seoul, Korea, Republic of
  Connect »

Seoul Clinical Site6

Seoul, Korea, Republic of
  Connect »

Seoul Clinical Site7

Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.